Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04520529

Acronym

LYMPHOTEQ

Enrollment

500

Registered

2020-08-20

Start date

2020-09-30

Completion date

2050-09-30

Last updated

2020-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Lymphoma

Brief summary

Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.

Interventions

OTHERBiologic Samples

* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care. * an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care. * In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age\> 18 years old * Informed consent signed by the patient * Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to WHO/ISCL/EORTC criteria

Exclusion criteria

* Patient under guardianship or curatorship * Lack of affiliation to social security

Design outcomes

Primary

Measure	Time frame
overall survival	5 years

Secondary

Measure	Time frame
Progression free survival	5 years
Overall survival	10 years

Contacts

Primary ContactAdèle DE MASSON

adele.demasson@aphp.fr01 42 49 43 19

Backup ContactMatthieu RESCHE-RIGON

matthieu.resche-rigon@univ-paris-diderot.fr0142499742

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026